As many as 136 million grownup People could also be eligible for Ozempic, researchers estimate.
In line with a examine revealed Monday in JAMA Community, among the many 25,531 members, 8,504 had been eligible for semaglutide.
Semaglutide, the lively drugs discovered within the drug, has change into a well-liked choice for individuals trying to drop a few pounds. Ozempic, together with Wegovy, has been broadly used, and each medicines are additionally used for the remedy of Kind 2 diabetes.
Amongst eligible adults, the imply age is 50.7 years previous, and 49 % are girls. The examine used knowledge from the Nationwide Well being and Diet Examination Survey to determine eligible adults.
Though many of the People who’re eligible for Ozempic based mostly on their “weight-management indication” will not be universally lined by payers, the examine estimates that greater than 39 million adults will qualify for the drug by indications aside from weight administration.
“The massive variety of US adults eligible for semaglutide highlights its potential impression on pharmaceutical spending and inhabitants well being,” the researchers wrote.
For the reason that drug has change into fashionable, the researchers wrote that quantifying the variety of People who’re eligible may information insurance policies for the “high-cost remedy.”
Ozempic and different weight-loss medicine have gained recognition in recent times. Different research have discovered it will probably assist with different circumstances, together with lowering the danger of COVID-19 deaths.
The analysis follows one other current examine, which discovered tirzepatide, the drugs present in weight reduction medicine Zepbound and Mounjaro, diminished the severity of sleep apnea.
The examine additionally comes because the World Well being Group and Meals and Drug Administration have elevated their warnings these days of counterfeit remedy resembling the load loss medicine.
